Stocks · News reference

Wedbush Downgrades Foghorn Therapeutics to Neutral, Lowers Price Target to $2

Oct 2, 2026, 2:45 PMBenzinga Newsdesk

Wedbush analyst Robert Driscoll downgrades Foghorn Therapeutics (NASDAQ:FHTX) from Outperform to Neutral and lowers the price target from $10 to $2.

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Oct 2, 2026, 2:45 PM
Checked: Oct 2, 2026, 2:45 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaOct 2, 2026, 2:29 PMBenzinga Newsdesk
Foghorn Therapeutics shares are trading lower after multiple analyst firms lowered their respective price targets on the stock.
FHTX
BenzingaOct 2, 2026, 2:23 PMBenzinga Newsdesk
TD Cowen Downgrades Foghorn Therapeutics to Hold
TD Cowen analyst Yaron Werber downgrades Foghorn Therapeutics (NASDAQ:FHTX) from Buy to Hold.
FHTX
BenzingaOct 2, 2026, 1:08 PMBenzinga Newsdesk
Guggenheim Maintains Buy on Foghorn Therapeutics, Lowers Price Target to $5
FHTX